Project Grant R01CA288392

Award Date 6/1/24
Completion Date 5/31/29
Dollars Obligated $540K
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $704,882 to the University of Southern California (USC) to conduct research on defining the genetic basis of prostate cancer risk in African American families. The key objectives of this 5-year project are to: 1) enroll additional eligible affected and unaffected family members from the existing RESPOND cohort to study genetic factors...
This federal Project Grant award of $564,543 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in prostate cancer. The key objectives are to: Determine the conditions that allow the growth-suppressive AR transcriptional programs to be reactivated in prostate cancer cells. Establish the clinical implications of oncogenic versus...
This $535,334 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research by Albert Einstein College of Medicine to investigate the non-autonomous role of androgen signaling in prostate tumorigenesis. The research aims to elucidate how androgen receptor activation in prostatic stromal cells, particularly those expressing the Gli1 transcription factor, promotes oncogenic transformation and tumor development in adjacent prostate...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $156,000.00 to Thomas Jefferson University's Sidney Kimmel Medical College to conduct whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic castration-resistant prostate cancer (mCRPC). The goal is to identify race-specific mutational signatures and evaluate their associations with racial survival disparities in mCRPC....
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $632,906 to Tulane University to conduct research on the role of the androgen receptor (AR) in promoting prostate cancer progression and therapeutic resistance. The key products and services to be delivered under this 5-year grant include: Elucidating the impact of AR-RNA interactions in prostate cancer progression and resistance to AR-targeting therapies. The research will also...
This Project Grant award of $248,847, provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research), will support research to investigate the role of mitochondrial dysfunction in driving aggressive prostate cancer, particularly in high-risk populations such as African American men. The key objectives are to: Identify mitochondrial DNA (mtDNA) alterations in prostate cancer mouse models and assess their clinical relevance for prostate cancer disparities. Use...
The National Cancer Institute (NCI) awarded a $1,620,203 Cooperative Agreement under the federal Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Southern California (USC) to lead the RESPOND cohort study. The study aims to identify social, environmental, and biological factors associated with prostate cancer progression and survival among African American men. Over 5 years, the project will recruit over 12,700 African American men diagnosed with prostate cancer...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $260,250 to Health Research, Inc. (a not-for-profit research organization located in Buffalo, NY) to investigate "The Role of SLC45A3-ELK4 Chimera as a Molecular Determinant of Prostate Cancer Health Disparity." The research aims to advance the understanding of genetic mechanisms underlying prostate cancer progression and health...
This Project Grant award from the National Cancer Institute (NCI) under the federal Cancer Cause and Prevention Research program (CFDA 93.393) supports research to investigate the contribution of germline copy number variations (CNVs) to the risk and aggressiveness of prostate cancer in men of African and European ancestry. The $613,220 award to the University of Southern California (USC) will leverage existing genome-wide association study (GWAS), whole-exome sequencing (WES), and...
This $717,667 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support the development of an artificial intelligence-enabled, stroma-weighted automated grading system (SWAG) to improve risk stratification for prostate cancer in Black men. The key objectives are to: 1) Annotate histological and multiphoton microscopy images to create a compendium of prostate cancer features, and develop a machine learning-based SWAG system for...

ABERRANT ACTIVATION OF ANDROGEN SIGNALING PATHWAYS IN AFRICAN AMERICAN PROSTATE CANCER - PROJECT SUMMARY AFRICAN AMERICAN (AA) MEN HAVE AN INCREASED RISK FOR BOTH PROSTATE CANCER (PCA) INCIDENCE AND MORTALITY. ALTHOUGH SOCIO-ECONOMIC STATUS AND OTHER ENVIRONMENTAL AND CULTURAL FACTORS LIKELY CONTRIBUTE TO THIS RACIAL DISPARITY, EMERGING EVIDENCE HAS SHOWN AN IMPORTANT ROLE OF GENETIC AND EPIGENETIC FACTORS IN THE PATHOGENESIS OF AA PCA. ANDROGENS AND THE ANDROGEN RECEPTOR (AR)-MEDIATED SIGNALING PATHWAYS PLAY A CENTRAL ROLE IN PROSTATE TUMORIGENESIS. THE AR IS A LIGAND-INDUCED TRANSCRIPTIONAL FACTOR AND CONTAINS AN N-TERMINAL TRANSACTIVATION DOMAIN (NTD). THE NTD OF HUMAN AR POSSESSES POLYMORPHIC TRINUCLEOTIDE REPEATS, CAGS (CYTOSINE, ADENINE, GUANINE), WHICH CODES FOR THE POLYGLUTAMINE (POLYQ) TRACT. THE LENGTH OF CAG REPEATS IN THE HUMAN AR GENE HAS BEEN SHOWN TO BE INVERSELY CORRELATED WITH THE RISK OF DEVELOPING PCA, AGE OF DISEASE ONSET, AND RISK OF ADVANCED PCA AT DIAGNOSIS. INTRIGUINGLY, AA MEN BEAR SHORTER CAG REPEATS SIGNIFICANTLY MORE FREQUENTLY THAN CAUCASIAN AMERICAN (CA) MEN, LINKING THE LENGTH OF POLYQ TRACTS TO THE PATHOGENESIS OF PCA IN AA MEN. ADDITIONALLY, A SIGNIFICANT CO-ACTIVATION OF THE ANDROGEN AND WNT SIGNALING PATHWAYS HAS BEEN REVEALED IN FAST GROWING AND EARLY ONSET PCA, SPECIFICALLY ENRICHED IN AA PCA SAMPLES. MOREOVER, EMERGING EVIDENCE HAS SHOWN A NICHE ROLE OF STROMAL AR TO SUPPORT PROSTATIC EPITHELIAL ONCOGENESIS. HOWEVER, DESPITE THESE INTRIGUING FINDINGS AND PAST SCIENTIFIC PROGRESS, THE ONCOGENIC ROLE AND RELATED MOLECULAR MECHANISM FOR AR-MEDIATED SIGNALING PATHWAYS IN PCA TUMORIGENESIS, SPECIFICALLY IN AA PCA RACIAL DISPARITY, REMAIN ELUSIVELY. ONE OF THE BOTTLENECKS FOR THESE SHORTFALLS IS THE LACK OF BIOLOGICALLY RELEVANT ANIMAL MODELS THAT CAN RECAPITULATE ABERRANT AR ACTIVATION IN PROMOTING PCA DEVELOPMENT AND PROGRESSION, MIMICKING THE SITUATION IN AA PATIENTS. TO DIRECTLY ADDRESS THIS CHALLENGE, WE PROPOSE A SERIES OF EXPERIMENTS USING OUR NEW AND RELEVANT ANIMAL MODELS, HUMAN PCA SAMPLES, SINGLE-CELL RNA SEQUENCING, AND OTHER ADVANCED APPROACHES TO DIRECTLY TEST OUR CENTRAL HYPOTHESIS THAT ABERRANT ACTIVATION OF THE AR BEARING SHORT POLYQ TRACTS IN BOTH PROSTATIC EPITHELIA AND STROMA PROMOTES PCA INITIATION, PROGRESSION, AND HORMONE REFRACTORINESS IN AA PATIENTS. SUCCESSFUL COMPLETION OF THE PROPOSED STUDY SHOULD DIRECTLY IMPACT THE CURRENT PARADIGMS AND LEAD TO THE DEVELOPMENT OF NEW PREVENTIVE AND THERAPEUTIC STRATEGIES TO IMPROVE CLINICAL OUTCOMES FOR AA PCA PATIENTS.

Posted 5/29/24, 12:00 AM